4606-65-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Piperidinemethanol is used as a reactant for the synthesis of various pharmaceutical compounds, including:
1. CB2 receptor agonists for the treatment of chronic pain, which can provide relief by targeting the CB2 receptors in the body.
2. Spiroimidazolidinone NPC1L1 inhibitors, which are being investigated for their potential in treating conditions related to cholesterol transport and absorption.
3. Quorum sensing modulators, which can interfere with bacterial communication and have potential applications in combating antibiotic resistance.
4. Protein lysine methyltransferase G9a inhibitors, which are involved in epigenetic regulation and may have implications in the development of therapies for various diseases.
5. P2Y12 antagonists for inhibition of platelet aggregation, which can be used in the treatment of cardiovascular conditions, such as preventing blood clots.
6. Soluble epoxide hydrolase inhibitors, which have potential applications in treating inflammatory and cardiovascular diseases by modulating the balance of eicosanoids.

InChI:InChI=1/C6H13NO/c8-5-6-2-1-3-7-4-6/h6-8H,1-5H2/p+1/t6-/m0/s1

Upstream product

• 614-18-6 3-pyridinecarboxylic acid ethyl ester 
• 131080-21-2 (1-Allyl-[3]piperidyl)-methanol 
• 405061-52-1 N-Cbz-3-hydroxymethylpiperidine 
• 1221818-73-0 (3S,5R)-Piperidine-1,3,5-tricarboxylic acid benzyl ester dimethyl ester 
• 37675-18-6 (S)-(+)-nipecotic acid ethyl ester 
• 851956-01-9 (S)-(+)-3-piperidinecarboxylic acid hydrochloride 
• 71962-74-8 Ethyl nipecotate 
• 140645-20-1 t-butyl (R,S)-3-<(butyryloxy)methyl>-1-piperidine-carboxylate 
• 383865-57-4 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine 
• 3367-95-1 N,N-diethylpiperidine-3-carboxamide 
• 5621-43-2 diethyl 2-methyleneglutarate 
• 175694-36-7 (3R,5S)-Piperidine-1,3,5-tricarboxylic acid 1-benzyl ester 3-methyl ester 
• 88466-73-3 Z-β²hPro-OMe 
• 140695-84-7 tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate 

Downstream Products

• 75431-18-4 3-(Hydroxymethyl)piperidine-N-carbamoyl chloride 
• 136866-85-8 1-acetyl-3-(hydroxymethyl)piperidine 
• 85387-44-6 1-benzyl-3-(hydroxymethyl)piperidine 
• 39945-51-2 benzyl 3-(hydroxymethyl)-1-piperidinecarboxylate 
• 101768-07-4 Toluene-4-sulfonic acid 1-(toluene-4-sulfonyl)-piperidin-3-ylmethyl ester 
• 3947-52-2 3-chloromethylpiperidine hydrochloride 
• 415722-06-4 [1-(4-methylbenzyl)-3-piperidinyl]methanol 
• 90287-71-1 3-(3-Hydroxymethyl-piperidin-1-ylmethyl)-phenol 
• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 205242-48-4 (1-Trityl-piperidin-3-yl)-methanol 
• 131774-16-8 1-[1-(3-hydroxymethyl-piperidino)-cyclohexan-1-yl]-carbonitrile 
• 170749-87-8 (1-Benzhydryl-piperidin-3-yl)-methanol 

Relevant academic research and scientific papers

Manganese Catalyzed Hydrogenation of Enantiomerically Pure Esters

A manganese-catalyzed hydrogenation of esters has been accomplished with TONs up to 1000, using cheap, environmentally benign, potassium carbonate and simple alcohols as activator and solvent, respectively. The weakly basic conditions lead to good functional group tolerance and enable the hydrogenation of enantiomerically enriched α-chiral esters with essentially no loss of stereochemical integrity.

O-(α-Phenylethyl)hydroxylamine as a ‘chiral ammonia equivalent’: synthesis and resolution of 5-oxopyrrolidine- and 6-oxopiperidine-3-carboxylic acids

An approach to the synthesis and resolution of five- and six-membered lactams (i.e., 5-oxopyrrolidine- and 6-oxopiperidine-3-carboxylic acids) is described. The method relies on the one-pot Michael reaction—cyclization of itaconic acid or diethyl homoitaconate and enantiopure O-(α-phenylethyl)hydroxylamine as a ‘chiral ammonia equivalent’. It is shown that this chiral auxiliary can be used for the separation of diastereomeric lactam products and then easily removed by catalytic hydrogenolysis.

PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED 3-HYDROXYMETHYLPIPERIDINE

The present invention relates to a process for preparing enantiomerically enriched 3-hydroxymethylpiperidine and in particular of the S-enantiomer of (S)-3-hydroxymethyl- piperidine in high chemical and optical purity. The invention also relates to extremely pure (S)-3-hydroxymethylpiperidine and (R)-3-hydroxymethylpiperidine.

Pyridone azo compound, tautomer thereof, and colorant-containing curable composition, color filter and manufacturing method thereof

The invention provides a pyridone azo compound represented by the following Formula (I) and a tautomer thereof. R1, R3 and R4 each independently represent a hydrogen atom, an alkyl group having 1 to 21 carbon atoms, an alkenyl group having 2 to 21 carbon atoms, an aryl group having 6 to 21 carbon atoms, an aralkyl group having 7 to 21 carbon atoms, or a substituent having a hetero atom; at least one of R1, R3 and R4 represents a substituent having a hetero atom; R3 and R4 may be formed into a heterocycle together with a jointly bonded nitrogen atom; and R2 represents an alkyl group having 1 to 10 carbon atoms, a methoxymethyl group, or a trifluoromethyl group. The invention further provides a colorant-containing curable composition and a color filter which contain the pyridone azo compound of Formula (I) and/or a tautomer thereof as a colorant.

FARNESYL PROTEIN TRANSFERASE INHIBITORS

Disclosed are compounds of formula (1.0), wherein R represents a cyclic moiety to which is bound an imodazolylalkyl group; R represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.

FUSED BENZENE DERIVATIVE AND USE

The present invention provides a compound represented by the general formula: [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X1 represents carbon atom, X2 represents a carbon atom, an oxygen atom, etc., W represents a nitrogen atom, etc., Y11 represents a group represented by the formula CR2R3' (wherein R2 represents a hydrogen atom, a cyano group, a nitro group, etc., and R3' represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), Y21 represents a group represented by the formula CR4R5' (wherein R4 represents a hydrogen atom, a cyano group, a nitro group, etc., and R5' represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), etc., and R1 represents an electron-withdrawing group, respectively. The formula represents a single bond or a double bond] or a salt thereof, which is useful as an androgen receptor modulator.

Chemoselective deprotection of allylic amines catalyzed by Grubbs' carbene

A commercially available ruthenium complex (first generation Grubbs' carbene) was used for the catalytic deprotection of allylic amines (secondary as well as tertiary), by using for the first time reagents different from palladium catalysts. Interestingly, the catalytic system directs the reaction toward the selective deprotection of allylamines in the presence of allylic ethers.

Novel farnesyl protein transferase inhibitors as antitumor agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Novel farnesyl protein transferase inhibitors as antitumor agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

NOVEL AMIDE DERIVATIVES

This invention relates to compounds which are represented by the general formula [I] ???[in which A stands for a group of the following formula [ao] or [b0] ???Ar1, Ar2 and Ar3 stand for optionally substituted phenyl; k stands for 0 or 1; m, n and s stand for 0, 1 or 2; R1 stands for hydrogen or optionally substituted lower alkyl; R2, R3, R4 and R5 either stand for hydrogen or optionally substituted lower alkyl, or R2 and R3, or R4 and R5 together stand for trimethylene and the like; R60 stands for hydrogen, alkyl, or the like; R61and R71 either stand for alkyl and the like, or together stand for trimethylene and the like; X stands for carbonyl or methylene; Y stands for nitrogen or methine; and Q- stands for anion], and the like. The compounds of the invention exhibit selective antagonism to muscarinic M3 receptors, and therefore are useful as safe and effective agents showing little side effect, for treating diseases of the respiratory, urinary and digestive systems.